STOCK TITAN

Biora Therapeutics, Inc. - BIOR STOCK NEWS

Welcome to our dedicated news page for Biora Therapeutics (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on Biora Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biora Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biora Therapeutics 's position in the market.

Rhea-AI Summary
Biora Therapeutics, Inc. has submitted an updated Investigational New Drug (IND) application for BT-600 to the FDA. The update includes additional information and extends the regulatory review period. BT-600 is a drug/device combination using Biora's NaviCap™ ingestible drug delivery device with a liquid formulation of tofacitinib for ulcerative colitis. The phase 1 clinical trial will evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Summary
Biora Therapeutics provides an update on its IND application for BT-600, a drug/device combination for the treatment of ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.93%
Tags
-
Rhea-AI Summary
Biora Therapeutics presents positive data on oral delivery of GLP-1 receptor agonist using BioJet platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
Rhea-AI Summary
Biora Therapeutics submits IND application for BT-600, a drug/device combination for ulcerative colitis treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
-
Rhea-AI Summary
Athyrium Capital Management increases equity exposure through convertible notes exchange at a 44% premium to closing price, resulting in $50 million debt reduction. On track to file an IND this month for NaviCap™ BT-600 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary
Biora Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
conferences
Rhea-AI Summary
Biora Therapeutics achieves device performance targets for BioJet platform, enabling testing of pharma collaborators' molecules. Confirmed achievement of greater than or equal to 15% average bioavailability. Progress towards meaningful partnerships expected this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.4%
Tags
none
-
Rhea-AI Summary
Biora Therapeutics, Inc. (BIOR) reports successful device function study results in humans for NaviCap™ targeted oral delivery platform and BioJet™ systemic oral delivery platform. The company also strengthened its intellectual property position with additional patents. The company remains on track for a September IND filing for the BT-600 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences
Biora Therapeutics, Inc.

Nasdaq:BIOR

BIOR Rankings

BIOR Stock Data

23.04M
13.75M
7.91%
64.14%
4.42%
Medical Laboratories
Health Care and Social Assistance
Link
United States of America
SAN DIEGO

About BIOR

progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.